Inozyme Pharma, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Sanjay Subramanian, SVP, CFO & Head of BD of Inozyme Pharma, Inc., disposed of all his common stock, restricted stock units, and stock options as part of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share.
Inozyme Pharma's Chief Operating Officer, Matthew Winton, disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share.
Inozyme Pharma Director Axel Bolte disposed of common stock and stock options as part of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share, effective July 1, 2025.
Inozyme Pharma Director Lynne Sullivan reported the disposition of stock options as Inozyme Pharma, Inc. completed its merger with BioMarin Pharmaceutical Inc. at $4.00 per share, resulting in cash payouts for eligible options.
Inozyme Pharma, Inc. has been acquired by BioMarin Pharmaceutical Inc. for $4.00 per share in cash, with the merger effective July 1, 2025, resulting in the cancellation and cash conversion of outstanding equity awards.
Form 4: Inozyme Pharma Director Disposes Over 4.49 Million Shares Following BioMarin Merger Completion
Inozyme Pharma Director Robert Hopfner disposed of over 4.49 million shares of common stock at $4.00 per share following the completion of the merger with BioMarin Pharmaceutical Inc.
Form 4: Inozyme Pharma CEO & Chairman Douglas Treco Acquires Shares Through Employee Stock Purchase Plan
Inozyme Pharma, Inc.'s CEO and Chairman, Douglas A. Treco, acquired 2,815 shares of common stock at $0.74 per share through the company's Employee Stock Purchase Plan.
Sanjay Subramanian, SVP, CFO & Head of BD of Inozyme Pharma, Inc., acquired 6,813 shares of common stock through the company's Employee Stock Purchase Plan.
Inozyme Pharma, Inc.'s Chief Operating Officer, Matthew Winton, acquired 14,355 shares of common stock at $0.74 per share through the company's Employee Stock Purchase Plan.
Director Axel Bolte reports the acquisition and disposal of Inozyme Pharma (INZY) common stock and stock options on May 15, 2025.
CEO Douglas Treco of Inozyme Pharma reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Matthew Winton, COO of Inozyme Pharma, reports the acquisition of 2,490 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $0.77 per share.
Sanjay Subramanian, SVP, CFO & Head of BD at Inozyme Pharma, reports the purchase of 2,490 shares of common stock through the company's Employee Stock Purchase Plan.
Sanjay Subramanian, SVP and CFO of Inozyme Pharma, reports the acquisition of stock options and restricted stock units on March 11, 2025.
Inozyme Pharma's COO, Matthew Winton, reported the acquisition of stock options and restricted stock units in the company, according to a Form 4 filing with the SEC.
CEO Douglas A. Treco reports acquisition of stock options and restricted stock units in Inozyme Pharma, Inc.
Director Erik Harris of Inozyme Pharma, Inc. was granted stock options to purchase 56,000 shares of common stock at an exercise price of $5.06 on October 3, 2024.
Inozyme Pharma CEO Douglas Treco acquired 1,710 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.45 per share.
Inozyme Pharma's COO, Matthew Winton, reports acquiring 1,710 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.45 per share.
Director Edward T. Mathers acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024, vesting fully on June 18, 2025, or earlier upon the first annual stockholder meeting.
Director Robert Lorne Hopfner acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.
Director Reinaldo Diaz of Inozyme Pharma, Inc. was granted 28,000 stock options on June 18, 2024, according to a Form 4 filing with the SEC.
Director Lynne Marie Sullivan acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.
Director Sarah M. Bhagat acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024, according to a recent SEC filing.
Director Axel Bolte acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.
Director Martin Edwards acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024.
Inozyme Pharma CEO Douglas Treco reports the settlement of restricted stock units (RSUs) and subsequent sale of shares to cover tax obligations.
Inozyme Pharma's COO, Matthew Winton, reports acquiring 3,188 shares of common stock through the company's Employee Stock Purchase Plan.
Inozyme Pharma's COO, Matthew Winton, was granted stock options on March 13, 2024.
Inozyme Pharma CEO Douglas Treco reports the acquisition of stock options.